Press Releases and Blog
Blog
PBMs Provide More than $145 Billion in Value Annually for Americans
PBMs are your single biggest advocate for lower drug costs University of Chicago Professor of Economics and current Chief Counsel for Advocacy at the Small
Voices Across the Country Agree: PBMs Play a Critical Role in Making Drugs More Affordable
A multitude of policy analysts and economists have recently spoken out on the value of pharmacy benefit managers (PBMs). Satya Marar, visiting postgraduate fellow at
PCMA Recommends Streamlining Health Plan Requirements to Better Serve Medicare Beneficiaries
PCMA recently provided several recommendations to the Department of Health & Human Services (HHS) that would streamline and simplify requirements for Medicare Advantage and Part
Experts Highlight Critical Cost-Saving Role of PBMs to Lower Prescription Drug Costs
At a recent Federal Trade Commission (FTC) public listening session on “Lowering Americans’ Drug Prices Through Competition,” policymakers, academics, and industry leaders gathered to evaluate
PBMs: Your Friends Behind the Curtain
PBMs help the entire health care system by driving down prescription drug costs, saving money for patients and health plan sponsors. A new video explains the value
PBMs Are Launching Innovations That Put Patients First
A new Rx Research Corner blog post highlights how pharmacy benefit managers (PBMs) are responding to evolving changes in the market to better serve patients.
Press Releases
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the introduction of the Eliminating Thickets to Improve Competition (ETHIC) Act: “We applaud U.S. Senators Peter Welch (D-VT), Josh Hawley (R-MO), and Amy Klobuchar (D-MN) for introducing the Eliminating Thickets to Improve Competition (ETHIC) Act to support competition in the prescription drug market and address […]
(SPRINGFIELD, IL) — The Pharmaceutical Care Management Association (PCMA) released the following statement today following the signing of House Bill 1697 by Governor Pritzker: “We are disappointed with the misguided legislation that Governor Pritzker has signed that will hurt the ability of employers in Illinois to provide affordable health benefits to employees and their families. […]
(Sacramento, CA) — The Pharmaceutical Care Management Association (PCMA) released the following statement on Governor Gavin Newsom’s (D) budget proposal to lower prescription drug costs. “We applaud Gov. Newsom’s goal to lower prescription drug prices for California patients. Lowering prescription drug costs is an important step to improving California’s overall fiscal setting. “Specifically, we support […]
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released the following statement on the “Anticompetitive Conduct by Pharmaceutical Companies Impeding Generic or Biosimilar Competition” listening session, held jointly by the Federal Trade Commission (FTC), Department of Justice (DOJ), Department of Health and Human Services (HHS), and the Department of Commerce (DOC). “We applaud […]
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the United States Supreme Court’s decision to decline review of the 2023 ruling by the U.S. Court of Appeals for the Tenth Circuit in PCMA v. Mulready. The decision by the high court solidifies PCMA’s successful challenge to four provisions of […]
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the Restore Prescription Drugs Discount Act, introduced by U.S. Senator Rand Paul (R-KY): “We applaud Sen. Paul for introducing legislation to modernize the Robinson Patman antitrust statute. The Robinson Patman Act currently requires pharmacy benefit managers (PBMs) to use rebates as […]
ICYMI: New Reporting Highlights How Big Pharma Keeps Drug Prices High—And Patients Pay the Price
Recent reports from Bloomberg, Reuters, and JAMA offer a clear picture of how Big Pharma continues to drive up drug costs in the U.S., particularly
InsideSources: JC Scott – Drug Companies: Lower the List Price
The Administration’s recent proposal on drug prices rightly recognizes that Americans are getting ripped off by paying higher drug prices than anyone in the world,
Drug Companies Should Lower Rx List Prices
JC Scott: “The sticker price, set solely by the drug company, decides the starting point for all PBM and drug company negotiations.” PCMA president and
PCMA Urges CMS to Protect Pharmacies in Medicare Fair Price Program
Under the Inflation Reduction Act (IRA), for designated drugs that are negotiated by CMS in Medicare Part D, the pharmacy is no longer paid by
ICYMI: Experts Discuss Value of PBMs at Capitol Hill Briefing
What exactly are pharmacy benefit managers (PBMs) and why are policymakers hearing so much about them now? That was one of the questions answered as
ICYMI: Experts Discuss Value of PBMs at Capitol Hill Briefing
What exactly are pharmacy benefit managers (PBMs) and why are policymakers hearing so much about them now? That was one of the questions answered as
PBMs Innovating to Increase Biosimilar Use, Lower Rx Costs
Big Pharma Continues to Undermine Competition, Setting High Drug Prices to Boost Profits As the House Ways and Means Subcommittee on Health today holds a
PCMA Congratulates Dr. Mehmet Oz on His Confirmation to Lead the Centers for Medicare & Medicaid Services
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released a statement today following the U.S. Senate confirmation of Dr. Mehmet Oz, M.D. to serve
PBMs Work to Lower the Costs of GLP-1 Drugs
PBMs are facilitating coverage of these drugs for weight management, but Big Pharma companies are still shifting blame for their high prices onto PBMs.
PBMs Are Breaking Down Barriers to Expand Access to Biosimilars and Lower Consumer Costs
While Drug Companies Drive Up Drug Prices with Anti-Competitive Behavior, PBMs Continue to Innovate and Lower Costs for Consumers As policymakers tackle America’s prescription drug
